Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 398

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Frías, Juan P, Guja, Cristian, Hardy, Elise, Ahmed, Azazuddin, Dong, Fang, Öhman, Peter, Jabbour, Serge A·2016·The Lancet Diabetes & Endocrinology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(16)30267-4

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 3

  1. Lundkvist, 2016, Dapagliflozin QD and exenatide QW dual therapy: a 24-week randomized, placebo-controlled, phase 2 study examining effects on bodyweight and prediabetes in obese nondiabetic adults, Diabetes Obes Metab
  2. McGovern, 2015, Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) agonist in type 2 diabetes, Diabet Med, 32, 2
  3. García-Rubi E. Real life experience with the combination of exenatide LAR and dapagliflozin in obese type 2 diabetic patients in Mexico City. 26th American Association of Clinical Endocrinologists (AACE) Annual Scientific & Clinical Congress; Austin, TX, USA; May 3–7, 2016. 223 (abstr). · doi:10.1016/s1530-891x(20)44931-6

Cited by

See all 398

Metadata

Authors
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2016-12
Volume
4
Issue
12
Pages
1004-1016
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2519803668
Cited by
398
References
33
FWCI
46.47
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(16)30267-4
The paper
Frías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016). Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(16)30267-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.